Drug Profile
Obinepitide
Alternative Names: TM 30338Latest Information Update: 07 Jul 2010
Price :
$50
*
At a glance
- Originator 7TM Pharma
- Class Anorectics; Hormones; Obesity therapies
- Mechanism of Action Neuropeptide Y2 receptor agonists; Neuropeptide Y4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 12 Jun 2007 Phase-II clinical trials in Obesity in Sweden (SC)
- 09 May 2006 Phase I/II clinical studies of TM 30338 have been completed in diabetes
- 07 Jul 2005 Phase-I/II clinical trials in Obesity in Denmark (unspecified route)